In 725 adults with obesity or overweight with a complication (no diabetes), weekly survodutide 3.6 mg or 6.0 mg cut weight by 12.2% and 13.0% at 76 weeks vs 5.4% with placebo; GI adverse events in 80.9% and 89.7% vs 47.9%.
RCTn = 725
le Roux et al. Survodutide Once Weekly for the Treatment of Adults with Obesity